Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable

Clinical response was maintained at 73.2% for Psoriasis Area and Severity Index (PASI) 75 with three years of continuous Sotyktu treatment in the POETYK PSO long-term extension trialSotyktu demonstrated a consistent safety profile with no increases in adverse events or serious adverse events and no emergence of any...

Related Keywords

Berlin , Germany , California , United States , April Armstrong , Bristol Myers Squibb , Los Angeles , Roland Chen , Exchange Commission , Venereology Congress , Bristol Myers Squibb Company Adverse Event , Instagram , Linkedin , Program To , Laboratory Abnormalities , Neuroscience Development , Facebook , Twitter , Amgen Inc , University Of California , Clinical Trial Program , Youtube , European Academy Of Dermatology , Psoriasis Area , Severity Index , Dermatology Bristol Myers Squibb , Global Assessment , European Academy , Bristol Myers , Myers Squibb , Pioneering Paths Forward , Transform Patient , Risks Related , Janus Kinase , Bristol Myers Squibb Company , Adverse Event , Prescribing Information , Medication Guide , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports ,